Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine

Key facts

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Principal Investigator

Kawsar Talaat, MD

Johns Hopkins Bloomberg School of Public Health

Intervention

H6N1 Teal HK 97/AA ca recombinant vaccine(biological)

Enrollment

22 enrolled

Eligibility

18-49 years · All sexes

Timeline

2008

Study locations (1)

• Johns Hopkins Bayview Medical Center, CIR Unit at the Mason F Lord Building, Baltimore, Maryland, United States

Collaborators

Johns Hopkins Bloomberg School of Public Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Avian influenza

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07496450
  A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
  ModernaTX, Inc.
• RECRUITINGPHASE3NCT07240558
  Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
  University Health Network, Toronto
• ACTIVE NOT RECRUITINGPHASE4NCT07275060
  Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
  Canadian Immunization Research Network
• RECRUITINGPHASE1, PHASE2NCT06842173
  Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
  Butantan Institute
• ACTIVE NOT RECRUITINGPHASE1NCT07019883
  A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGNANCT06850298
  H5N1 Milk Detection Study
  Emory University

See all trials for Avian influenza →